Soleno Therapeutics, Inc. (SLNO) Securities Fraud Class Action Lawsuit Filed; May 5, 2026, Lead Plaintiff Deadline

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for alleged material misstatements and omissions regarding its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR) [1] Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases [1] - The company's only commercial product is DCCR, aimed at treating hyperphagia in individuals with Prader-Willi syndrome (PWS) [1] Lawsuit Details - The class action lawsuit covers investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 [1] - Allegations include that the company downplayed and concealed significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [1] - The lawsuit claims that these misrepresentations led to materially lower commercial viability for DCCR and undisclosed risks associated with its launch [1] Stock Performance - Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26% due to concerns raised by a report from Scorpion Capital regarding the Phase 3 clinical trial program [1] Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options and to file for lead plaintiff status by May 5, 2026 [1] - The firm operates on a contingency fee basis, meaning there is no cost to the investors for legal representation [1]